I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., May 31, 2022 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed…